Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity

Abstract

patients with significant comorbidity who are fit to undergo cisplatin-based CCRT achieve median survivals similar to that reported in phase III trials and with relatively few late toxic effects.

Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer

“…This may have resulted in a highly selected patient cohort, which could in turn limit the generalizability of the conclusions and introduce confounders. Furthermore, the median radiological follow-up of 9.4 months in the present cohort is less than median survival observed in patients treated using CCRT outside clinical trials [16]. The fact that correlations were not observed between RLD changes and patient factors, dosimetric parameters and clinical RP, is likely due to the limited power with this sample size and the lack of a longer follow-up.…”

“…Of 89 stage III NSCLC patients described in our definite CCRT cohort [16], 50 were treated with both chemo-and radiotherapy at the VU University Medical Center. Of these, 25 patients were excluded for the following reasons: no available follow-up scans (n = 7); disease progression within 3 months after last radiotherapy (n = 7); difficulty with registration due to atelectasis (n = 4) or fistula/empyema (n = 2); previous pneumonectomy (n = 2); death during treatment (n = 2), and drop-out of CCRT after 40 Gy (n = 1).…”

“…Patients with stage III NSCLC who were treated using thoracic radiotherapy and concurrent full-dose cisplatin-etoposide between 2003 and 2008 [16] were assessed for eligibility in this retrospective study. Eligible patients were required to have at least one CT-scan performed >3 months after completion of CCRT, and both chemotherapy and follow-up CT-scans had to be performed at our center.…”

Clinical analysis of concurrent chemoradiotherapy in 83 patients with locally advanced non-small cell lung cancer

“…NP group: Navelbine (NVB) 20 mg/m 2 intravenous infusion on days 1, 8,22,29,43,50,64,71. Cisplatin (PDD), 80 mg/m 2 intravenous infusion days on 1, 22, 43, and 64 [2] . EP group: VP-16 100 mg/m 2 IV drip days on 1-3, 22-24, 43-45, 64-66, the dose of cisplatin is the same dose of cisplatin in NP group [3] .…”

Chemoradiation therapy in nonsmall cell lung cancer

“…More than half of the patients with stage III are currently thought to be ineligible for concurrent regimens, if inclusion is restricted to patients less than 75 years and those with less than two serious comorbidities [8]. However, comorbidity does not correlate per se with treatment outcome in patients fit enough for chemoradiation therapy (CRT) [9]. The exact contribution of comorbidity, age and other clinical parameters to the reported toxicity is unclear, and preliminary data suggest that clinical selection could be less strict.…”